| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 694 | 2020 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 671 | 2017 |
| Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer HL Gomez, DC Doval, MA Chavez, PCS Ang, Z Aziz, S Nag, C Ng, ... Journal of Clinical Oncology 26 (18), 2999-3005, 2008 | 416 | 2008 |
| Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer LS Schwartzberg, SX Franco, A Florance, L O'Rourke, J Maltzman, ... The oncologist 15 (2), 122-129, 2010 | 271 | 2010 |
| A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer HJ Burstein, AM Storniolo, S Franco, J Forster, S Stein, S Rubin, ... Annals of Oncology 19 (6), 1068-1074, 2008 | 253 | 2008 |
| Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer H Rugo, E Shtivelman, A Perez, C Vogel, S Franco, E Tan Chiu, ... Breast cancer research and treatment 105, 17-28, 2007 | 124 | 2007 |
| A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer KL Blackwell, EH Kaplan, SX Franco, PK Marcom, JE Maleski, ... Journal of Clinical Oncology 22 (14_suppl), 3006-3006, 2004 | 119 | 2004 |
| Clinical experience with trastuzumab (herceptin) CL Vogel, SX Franco The breast journal 9 (6), 452-462, 2003 | 88 | 2003 |
| A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer O Rixe, SX Franco, DA Yardley, SR Johnston, M Martin, BK Arun, ... Cancer chemotherapy and pharmacology 64, 1139-1148, 2009 | 65 | 2009 |
| Breast cancer and human immunodeficiency virus: a report of 20 cases J Hurley, S Franco, C Gomez-Fernandez, I Reis, P Velez, P Doliny, ... Clinical breast cancer 2 (3), 215-220, 2001 | 57 | 2001 |
| Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study … J Gligorov, B Ataseven, M Verrill, M De Laurentiis, KH Jung, HA Azim, ... European Journal of Cancer 82, 237-246, 2017 | 52 | 2017 |
| A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer HS Rugo, A Jo Chien, SX Franco, AT Stopeck, A Glencer, S Lahiri, ... Breast cancer research and treatment 134, 13-20, 2012 | 51 | 2012 |
| Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience S Franco, A Perez, E Tan-Chiu, C Frankel, CL Vogel Breast cancer research and treatment 88, 103-108, 2004 | 35 | 2004 |
| Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma AF Cardona, L Rojas, B Wills, L Bernal, A Ruiz-Patiño, O Arrieta, ... Journal of Neuro-Oncology 136, 363-371, 2018 | 33 | 2018 |
| BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations AF Cardona, L Rojas, B Wills, O Arrieta, H Carranza, C Vargas, J Otero, ... Oncotarget 7 (42), 68933, 2016 | 31 | 2016 |
| A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC) HS Rugo, S Franco, P Munster, A Stopeck, W Ma, J Lyandres, S Lahiri, ... Journal of Clinical Oncology 26 (15_suppl), 1042-1042, 2008 | 28 | 2008 |
| La alimentación familiar una expresión del cuidado no remunerado S Franco Prácticas de oficio 6, 1-8, 2010 | 25 | 2010 |
| RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer A Moreno-Aspitia, AC Dueck, I Ghanem-Canete, T Patel, S Dakhil, ... Breast cancer research and treatment 138 (2), 427-435, 2013 | 22 | 2013 |
| Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC). M Dickler, S Franco, A Stopeck, W Ma, B Nulsen, J Lyandres, M Melisko, ... Cancer Research 69 (2_Supplement), 3133, 2009 | 19 | 2009 |
| An Open‐Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First‐Line HER2‐Positive Metastatic Breast Cancer FJ Esteva, SX Franco, MK Hagan, AM Brewster, RA Somer, W Williams, ... The Oncologist 18 (6), 661-666, 2013 | 17 | 2013 |
